October 13, 2014 | The Israeli pharmaceutical technology company Therapix Biosciences registered with the American Depository Receipts to begin trading on Wall Street’s OTCQB exchange. Therapix currently has a NIS 9.3 million market cap on the Tel Aviv Stock Exchange, and following the announcement, the company’s share price rose 10 percent only to drop by 11 percent in the subsequent days. Therapix now hopes that trading on Wall Street will improve its situation, as medical marijuana research companies have seen a downturn since the beginning of 2014. Therapix focuses on the advancement of specialty biopharmaceuticals, recently investing in medical marijuana company Lara Pharma.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments